Organization · Venture Capital
LAUXERA CAPITAL PARTNERS
Lauxera Capital Partners is an independent growth equity firm based in Paris and San Francisco, specializing in investments in healthtech companies at the early profitability stage. The firm focuses on commercial-stage medical devices, digital health, and life sciences tools.
Overview
What LAUXERA CAPITAL PARTNERS does
What LAUXERA CAPITAL PARTNERS is
Lauxera Capital Partners is an independent growth equity firm based in Paris and San Francisco, specializing in investments in healthtech companies at the early profitability stage. The firm focuses on commercial-stage medical devices, digital health, and life sciences tools.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2020
- Approximate age
- About 6 years
- Structured capabilities
- Funder
- Last reviewed
- April 10, 2026
Official channels
Find LAUXERA CAPITAL PARTNERS elsewhere
Open the official website or a supported primary organization account.
Capability profile
LAUXERA CAPITAL PARTNERS as a funder
Investment thesis
Lauxera Capital Partners focuses on investing in growth-stage healthtech companies that have achieved early profitability. The firm leverages its extensive experience to support businesses in scaling their operations and expanding globally.
Focus narrative
Lauxera Capital Partners invests in a variety of sectors within Healthtech, including medical devices, digital health, pharma services, life science tools, diagnostics, and healthtech IT and data. The firm targets companies that have reached breakeven or early profitability, emphasizing commercial execution as the primary driver of value creation.
Value beyond capital
Lauxera Capital Partners adds value to its portfolio companies by catalyzing growth through innovation, commercial investment, business development, and talent acquisition. The firm leverages its extensive network and expertise to help companies achieve their growth objectives and expand into new markets.
Terms and economics
- Typical check
- $22,000,000–$110,000,000
Focus and fit
- Stages
- Growth Equity
- Sectors
- Healthcare · Medical Devices · Digital Health · Diagnostics
- Regions
- EuropeNorth America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 12
- Recorded notable exits
- OrganOx
Portfolio context
Lauxera Capital Partners has invested in notable companies such as Acandis (neurovascular medical devices), Antaros Medical (imaging drug development), BioLamina (regenerative medicine tools), Caresyntax (surgical intelligence platform), Lifen (digital health integration), LUMICKS (protein and cell analysis), Matrix One (medtech compliance platform), Natural Cycles (non-hormonal contraception), OrganOx (liver transplant optimization), Ospi (healthtech data intelligence), Reapplix (advanced wound care), Synovo Group (patient transportation software), Veranex (medtech innovation services), and Verdot (bioprocess purification platforms).
Common questions
What to know about LAUXERA CAPITAL PARTNERS
Upseed classifies LAUXERA CAPITAL PARTNERS under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 10, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.